18 completed, 7 terminated, 3 active not recruiting, 3 recruiting. 35 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Completed 18, Terminated 7, Active not recruiting 3, Recruiting 3, Unknown 2, Withdrawn 2 |
| Phase 1 | 7 | Completed 3, Unknown 2, Active not recruiting 1, Terminated 1 |
Follow Prolymphocytic Leukemia: new trials by email Literature Review of Prolymphocytic Leukemia trials Research Report on Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Fludarabine, Melphalan, Total Body Irradiation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2019-12-06 | 2025-12-11 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders HSCT with TBI Regimen, HSCT with Non-TBI Regimen - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 300 | 2018-03-30 | 2026-06-25 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Infusion of Treg - Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2017-02-16 | 2020-09-29 |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Ibrutinib, Idelalisib - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2016-03-01 | 2017-09-27 | |
| Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis - Anemia, Cancer Fatigue | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2015-12-18 | 2019-10-29 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Fludarabine, Cyclophosphamide, Total body irradiation - Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 | 2015-12-01 | 2022-11-03 |
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation sotrastaurin acetate, pharmacological study, laboratory biomarker analysis - Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma | Phase 2 | Withdrawn | James Blachly | 2015-03-12 | 2017-04-05 | |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Acerta Pharma BV | 306 | 2014-01-30 | 2026-05-05 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Ibrutinib, Quality-of-Life Assessment, Questionnaire Administration - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 66 | 2013-12-06 | 2026-11-12 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Allogeneic Stem Cell Transplant for CLL Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2012-11-21 | 2020-02-24 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate - Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Phase 2 | Completed | Fred Hutchinson Cancer Center | 47 | 2012-09-25 | 2020-01-02 |
Showing 20 of 35. Sign in to see all of them.
Leukemia, Prolymphocytic (35) · Leukemia, Lymphocytic, Chronic, B-Cell (34) · Lymphoma, Mantle-Cell (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Leukemia, Myeloid, Acute (15) · Lymphoma, Follicular (15) · Burkitt Lymphoma (12) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (12) · Lymphoma, B-Cell, Marginal Zone (12) · Multiple Myeloma (11) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, Non-Hodgkin (10) · Myelodysplastic Syndromes (10) · Hodgkin Disease (9) · Primary Myelofibrosis (8)
Hemic and Lymphatic Diseases (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Leukemia, Lymphoid (35) · Lymphatic Diseases (35) · Lymphoproliferative Disorders (35) · Neoplasms (35) · Neoplasms by Histologic Type (35) · Chronic Disease (34) · Disease Attributes (34) · Leukemia, B-Cell (34) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Hematologic Diseases (33) · Leukemia (33)
Mycophenolic Acid (15) · Whole-Body Irradiation (14) · fludarabine phosphate (13) · Cyclophosphamide (12) · Cyclosporine (10) · Cyclosporins (9) · fludarabine (7) · Peripheral Blood Stem Cell Transplantation (6) · Antilymphocyte Serum (4) · Rituximab (4) · Sirolimus (4) · Tacrolimus (4) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · ibrutinib (3)
Fred Hutchinson Cancer Center (11) · Masonic Cancer Center, University of Minnesota (6) · Chinese PLA General Hospital (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · German CLL Study Group (2) · Acerta Pharma BV (1) · Case Comprehensive Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · James Blachly (1) · Kami Maddocks, MD (1) · Ohio State University Comprehensive Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (29) · Italy (4) · China (3) · Germany (3) · Denmark (2) · Austria (1) · United Kingdom (1)
David Maloney (3) · Mohamed Sorror (3) · Chitra Hosing (2) · Amy E DeZern, MD (1) · Ann E. Dahlberg (1) · Brenda Cooper, MD (1) · Brenda Sandmaier (1) · Claudio Brunstein, MD, PhD (1) · Claudio G. Brunstein, MD, PhD (1) · Erica Warlick, MD (1) · Georg Hopfinger (1) · James Blachly, MD (1) · Jan A Burger (1) · Jennifer Woyach, MD (1)
PMID 32499241, PMID 28714866, PMID 34515338, PMID 18997171, PMID 19706886, PMID 19826119, PMID 22289993, PMID 23512246, PMID 24990615, PMID 25444722, PMID 25596730, PMID 26182309, PMID 26641137, PMID 29263894, PMID 30530801, PMID 31088809, PMID 31876911, PMID 32245502, PMID 32603426, PMID 34608724, PMID 34735860, PMID 39563886, PMID 39716442, PMID 41043099, PMID 41044668, PMID 41804087, PMID 41915892
P30CA015704 (9), P01CA018029 (4), N01CM62207 (2), P01CA078902 (2), P30CA016672 (2), 2014 (1), 2023 (1), N01CM00070 (1), N01CM62202 (1), P01CA015396 (1), P30CA016058 (1), P50CA140158 (1), U01CA076576 (1), UM1CA186712 (1)